Trials / Completed
CompletedNCT03472313
Assessment of the Biodistribution and Safety of [18F]MNI-958 in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 2 (actual)
- Sponsor
- Invicro · Academic / Other
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The overall goal of this protocol is to evaluate the biodistribution of \[18F\]MNI-958 also known as APN-0000455 or PM-PBB3, as a tau targeted radiopharmaceutical.
Detailed description
The overall goal of this protocol is to evaluate the biodistribution of \[18F\]MNI-958 also known as APN-0000455 or PM-PBB3, as a tau targeted radiopharmaceutical. The specific objectives are: * To determine the radiation dosimetry of \[18F\]MNI-958 * To assess the safety and tolerability of a single dose of \[18F\]MNI-958
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | [18F]MNI-958 | Healthy Volunteers recruited for the study will undergo a single \[18F\]MNI-958 injection and PET scan. |
Timeline
- Start date
- 2017-11-14
- Primary completion
- 2018-04-20
- Completion
- 2018-04-20
- First posted
- 2018-03-21
- Last updated
- 2018-10-22
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03472313. Inclusion in this directory is not an endorsement.